Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN110951799B details a novel whole-cell enzymatic route for high-purity antibiotic intermediates, offering significant cost reduction and scalable manufacturing advantages.
Patent CN115109769B reveals L-threonine aldolase mutants enabling >99% conversion for L-serine synthesis. Discover cost-effective biocatalytic solutions for pharmaceutical intermediates.
Patent CN107721853A reveals enzymatic synthesis for latamoxef side chain. High purity, green process, cost reduction in pharma intermediate manufacturing.
Patent CN1302116C reveals a novel enzymatic route for high-purity cyclopentene intermediates, offering significant cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Patent CN116848257A enables green production of (R)-mandelic acid. Achieve cost reduction in pharmaceutical intermediates manufacturing with sustainable enzyme cascades.
Discover the advanced enzymatic method for producing high-purity fluvastatin diol. This patent-based insight highlights cost reduction and superior chiral selectivity for pharmaceutical manufacturing.
Patent CN114957030B reveals Rhodococcus erythropolis AJ270 catalyzed hydrolysis for high-purity chiral intermediates, offering cost reduction and supply chain reliability.
Patent CN105177069A details high-yield biocatalysis for chiral intermediates. Offers sustainable manufacturing and supply chain reliability for global pharmaceutical partners.
Patent CN105087668A reveals high-yield biocatalytic route for chiral intermediates. Achieve cost reduction and supply reliability with green manufacturing processes.
Patent CN105039435A details yeast biocatalysis for high-purity chiral intermediates. Achieve significant cost reduction and supply chain reliability with scalable green manufacturing.
Patent CN105087674A details high-yield biocatalytic synthesis. Offers supply chain stability and cost reduction in chiral intermediate manufacturing for global partners.
Patent CN105039433A reveals high-yield yeast catalysis. Offers supply chain stability and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN105087670A details high-yield biocatalytic synthesis. Offers supply chain stability and cost reduction in chiral intermediate manufacturing for global partners seeking reliable pharmaceutical intermediate supplier.
Novel enzyme process for chiral amine intermediate. High purity, mild conditions, scalable for pharma manufacturing.
Patent CN102337307A reveals a green biocatalytic route for high-purity phenyl glycidol intermediates. Eliminate metal residues and reduce costs with scalable enzymatic epoxidation technology.
Patent CN112011580B reveals a novel aldolase-catalyzed route for Droxidopa. Achieve high stereoselectivity and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN117402920A details a novel ketoreductase mutant for asymmetric reduction. This report analyzes cost reduction in chiral drug manufacturing and supply chain reliability for global buyers.
Patent CN106995807A enables high-purity Sitagliptin intermediate synthesis via recombinant transaminase, offering supply chain stability and cost efficiency.
Patent CN108753851B details a novel ChKRED12 enzyme method for producing high-purity chiral 1,2-diols, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN116949024B reveals mutant enzyme boosting conversion. Offers cost reduction and supply reliability for pharmaceutical intermediate manufacturing.